{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:53:11Z","timestamp":1791276791394,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00228-026-04185-6","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:02:09Z","timestamp":1789977729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Masking effect in the Spanish spontaneous reporting database FEDRA"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0436-0242","authenticated-orcid":false,"given":"Nuria","family":"Sols Cueto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2905-2475","authenticated-orcid":false,"given":"Mar\u00eda del Mar","family":"Guti\u00e9rrez-Lob\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4998-214X","authenticated-orcid":false,"given":"Araceli","family":"N\u00fa\u00f1ez Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7992-8933","authenticated-orcid":false,"given":"Cristina","family":"Fern\u00e1ndez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"#cr-split#-4185_CR1.1","unstructured":"European Commission (2026) Strengthening pharmacovigilance to reduce adverse effects of medicines. Brussels: MEMO\/08\/782"},{"key":"#cr-split#-4185_CR1.2","unstructured":"Dec 2008. Available from: https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/memo_08_782. Accessed 11 Feb"},{"issue":"1","key":"4185_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12911-019-0999-1","volume":"19","author":"R Liu","year":"2019","unstructured":"Liu R, Zhang P (2019) Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports. BMC Med Inf Decis Mak 19(1):279. https:\/\/doi.org\/10.1186\/s12911-019-0999-1","journal-title":"BMC Med Inf Decis Mak"},{"key":"4185_CR3","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Gu\u00eda para la detecci\u00f3n de se\u00f1ales del SEFV-H (2025) Available from: https:\/\/www.aemps.gob.es\/vigilancia\/medicamentosUsoHumano\/SEFV-H\/docs\/guia-senales-SEFV-H-2025.pdf. Accessed 23 Oct 2025"},{"key":"4185_CR4","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2025) Informes anuales del Sistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de Uso Humano (SEFV-H). Available from: https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/farmacovigilancia-de-medicamentos-de-uso-humano\/identificacion-de-riesgos\/sistema-espanol-de-farmacovigilancia-de-medicamentos-de-uso-humano\/. Accessed 23 Oct"},{"key":"4185_CR5","volume-title":"Los primeros 25 a\u00f1os del Sistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de Uso Humano","author":"G Manso Rodr\u00edguez","year":"2010","unstructured":"Manso Rodr\u00edguez G, Hidalgo Balsera A, de Abajo Iglesias FJ, Carvajal Garc\u00eda Pando A, coordinadores (2010) Los primeros 25 a\u00f1os del Sistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de Uso Humano. Ediciones de la Universidad de Oviedo, Oviedo. ISBN: 978-84-8317-830-0"},{"key":"4185_CR6","doi-asserted-by":"publisher","unstructured":"Wisniewski AF et al (2016) Good signal detection practices: evidence from IMI PROTECT. Drug Saf 39(6). https:\/\/doi.org\/10.1007\/s40264-016-0405-1","DOI":"10.1007\/s40264-016-0405-1"},{"issue":"6","key":"4185_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00002018-199716060-00002","volume":"16","author":"RH Meyboom","year":"1997","unstructured":"Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW (1997) Principles of signal detection in pharmacovigilance. Drug Saf 16(6):355\u2013365. https:\/\/doi.org\/10.2165\/00002018-199716060-00002","journal-title":"Drug Saf"},{"issue":"5","key":"4185_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/003591576505800503","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58(5):295. https:\/\/doi.org\/10.1177\/003591576505800503","journal-title":"Proc R Soc Med"},{"issue":"1","key":"4185_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00228-025-03928-1","volume":"82","author":"C Fernandez-Fernandez","year":"2026","unstructured":"Fernandez-Fernandez C, N\u00fa\u00f1ez Ventura A, Quiroga-Gonz\u00e1lez L, Guti\u00e9rrez-Lob\u00f3n MM, L\u00e1zaro-Bengoa E (2026) Trends and challenges in adverse drug reaction reporting in Spain: analysis of the FEDRA database (2019\u20132023). Eur J Clin Pharmacol 82(1):8. https:\/\/doi.org\/10.1007\/s00228-025-03928-1","journal-title":"Eur J Clin Pharmacol"},{"key":"4185_CR10","volume-title":"Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII","author":"CIOMS","year":"2010","unstructured":"CIOMS (2010) Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. Council for International Organizations of Medical Sciences, Geneva"},{"issue":"8","key":"4185_CR11","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00228-020-02894-0","volume":"76","author":"C Fernandez-Fernandez","year":"2020","unstructured":"Fernandez-Fernandez C, L\u00e1zaro-Bengoa E, Fern\u00e1ndez-Ant\u00f3n E, Quiroga-Gonz\u00e1lez L, Montero Corominas D (2020) Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain\u2014differences between regional pharmacovigilance centres and pharmaceutical industry. Eur J Clin Pharmacol 76(8):1175\u20131181. https:\/\/doi.org\/10.1007\/s00228-020-02894-0","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4185_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18(6):427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4185_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"4185_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroeks","year":"2002","unstructured":"van Puijenbroeks EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4185_CR13","unstructured":"European Medicines Agency. Screening for adverse reactions in EudraVigilance (2016) Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf. Accessed Oct 23, 2025"},{"issue":"16","key":"4185_CR14","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","volume":"27","author":"GN Nor\u00e9n","year":"2008","unstructured":"Nor\u00e9n GN, Sundberg R, Bate A, Edwards IR (2008) A statistical methodology for drug\u2013drug interaction surveillance. Stat Med 27(16):3057\u20133070. https:\/\/doi.org\/10.1002\/sim.3247","journal-title":"Stat Med"},{"issue":"7","key":"4185_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","volume":"41","author":"R Postigo","year":"2018","unstructured":"Postigo R, Brosch S, Slattery J, van Haren A, Dogn\u00e9 JM, Kurz X et al (2018) EudraVigilance medicines safety database: publicly accessible data for research and public health protection. Drug Saf 41(7):665\u2013675. https:\/\/doi.org\/10.1007\/s40264-018-0647-1","journal-title":"Drug Saf"},{"issue":"5","key":"4185_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M (2008) VigiBase, the WHO global ICSR database system: basic facts. Ther Innov Regul Sci 42(5):409\u2013419. https:\/\/doi.org\/10.1177\/009286150804200501","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"4185_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","volume":"39","author":"MA Maci\u00e1-Mart\u00ednez","year":"2016","unstructured":"Maci\u00e1-Mart\u00ednez MA, de Abajo FJ, Roberts G et al (2016) An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf 39(1):29\u201343. https:\/\/doi.org\/10.1007\/s40264-015-0351-3","journal-title":"Drug Saf"},{"key":"4185_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/pds.3530","volume":"23","author":"F Maignen","year":"2014","unstructured":"Maignen F, Hauben M, Hung E, Van Holle L, Dogn\u00e9 J-M (2014) A conceptual approach to the masking effect of measures of disproportionality. Pharmacoepidemiol Drug Saf 23:208\u2013217. https:\/\/doi.org\/10.1002\/pds.3530","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4185_CR19","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/pds.2022","volume":"19","author":"A Pariente","year":"2010","unstructured":"Pariente A, Didailler M, Avillach P, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Moore N (2010) A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf 19:1166\u20131171. https:\/\/doi.org\/10.1002\/pds.2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"4185_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/pds.3474","volume":"22","author":"K Juhlin","year":"2013","unstructured":"Juhlin K, Ye X, Star K, Nor\u00e9n GN (2013) Outlier removal to uncover patterns in adverse drug reaction surveillance\u2014a simple unmasking strategy. Pharmacoepidemiol Drug Saf 22(10):1119\u20131129. https:\/\/doi.org\/10.1002\/pds.3474","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4185_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12911-020-1037-z","volume":"20","author":"JX Wei","year":"2020","unstructured":"Wei JX, Ding Y, Li M, Sun J (2020) A stratification method based on clustering for the minimization of data masking effect in signal detection. BMC Med Inf Decis Mak 20:18. https:\/\/doi.org\/10.1186\/s12911-020-1037-z","journal-title":"BMC Med Inf Decis Mak"},{"issue":"11","key":"4185_CR22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/pds.4623","volume":"27","author":"C Dodd","year":"2018","unstructured":"Dodd C et al (2018) Masking by vaccines in pediatric drug safety signal detection. Pharmacoepidemiol Drug Saf 27(11):1249\u20131256. https:\/\/doi.org\/10.1002\/pds.4623","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4185_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40264-022-01186-z","volume":"45","author":"R Harpaz","year":"2022","unstructured":"Harpaz R et al (2022) Signaling COVID-19 vaccines adverse events. Drug Saf 45:765\u2013780. https:\/\/doi.org\/10.1007\/s40264-022-01186-z","journal-title":"Drug Saf"},{"key":"4185_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s40264-023-01346-9","volume":"46","author":"B Micallef","year":"2023","unstructured":"Micallef B et al (2023) An exploratory study of the impact of COVID-19 vaccine spontaneous reporting on masking signal detection in EudraVigilance. Drug Saf 46:1089\u20131103. https:\/\/doi.org\/10.1007\/s40264-023-01346-9","journal-title":"Drug Saf"},{"key":"4185_CR25","doi-asserted-by":"publisher","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","volume":"13","author":"D Montes-Grajales","year":"2023","unstructured":"Montes-Grajales D, Garcia-Serna R, Mestres J (2023) Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events. Sci Rep 13:18817. https:\/\/doi.org\/10.1038\/s41598-023-46275-w","journal-title":"Sci Rep"},{"key":"4185_CR26","doi-asserted-by":"publisher","unstructured":"Rachwal O, et al (2026) Evaluating COVID\u201119 vaccine masking and unmasking methods in two national pharmacovigilance databases. Drug Saf. https:\/\/doi.org\/10.1007\/s40264-025-01644-4","DOI":"10.1007\/s40264-025-01644-4"},{"key":"4185_CR31","unstructured":"EMA\/HMA (2013) Guideline on good pharmacovigilance practices (GVP). Product \u2011or population\u2011specific considerations I: vaccines for prophylaxis against infectious diseases. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-i-vaccines-prophylaxis-against-infectious-diseases_en.pdf.\u00a0Accessed 23 Oct 2025"},{"issue":"2","key":"4185_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S (1999) The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 20(2):109\u2013117. https:\/\/doi.org\/10.2165\/00002018-199920020-00002","journal-title":"Drug Saf"},{"issue":"1","key":"4185_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22(1):57\u201369","journal-title":"Stat Methods Med Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04185-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:27:44Z","timestamp":1791275264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04185-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4185"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04185-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments. As this research involved the analysis of anonymized data from SRS and did not involve any intervention or interaction with human subjects, formal ethical approval was not required. All data used are de-identified, ensuring the protection of patient confidentiality.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (no identifiable personal data are included).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study are from the FEDRA database of the Spanish Pharmacovigilance System for Medicines for Human Use (SEFV-H), which is managed by the Spanish Agency of Medicines and Medical Devices (AEMPS). The results, discussion and conclusions of this study are solely those considered by the authors and they do not represent in any way whatsoever the position of the SEFV-H or the AEMPS regarding this subject.","order":5,"name":"Ethics","label":"<b>Authors\u2019 note<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"254"}}